At Zeal Bio, Alan Bash recommended shutting down operations when the science failed to show sufficient conviction for investors. This tough but pragmatic decision, made sooner rather than later, was respected by investors as it prevented further capital loss on a non-viable program.

When a promising ALS drug failed Phase 2 trials, the company shut down. The drug's original founder, Dr. Ari Azhir, still believed in the science, repurchased the asset and all its data, and ultimately uncovered its true potential, leading to a new FDA application.

Summit Therapeutics' decision to pull its $500M offering illustrates a key risk. The public knowledge that the company needs capital but was unhappy with the price creates an overhang, as investors may now wait for a future, potentially discounted, financing event, putting downward pressure on the stock.

Voyager CEO Al Sandrock supports the FDA's use of accelerated approval for severe diseases but argues it must be coupled with industry accountability. He praises Amelix for voluntarily pulling its ALS drug after a failed confirmatory trial, framing such responsible actions as essential for maintaining the FDA's willingness to be flexible with approvals based on surrogate endpoints.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

A decade ago, Neurocrine made the difficult decision to pause development of a promising CRF2 agonist. This ruthless prioritization freed up essential capital and focus to successfully develop what became INGREZZA, their blockbuster drug, demonstrating a long-term strategy of sacrificing a good opportunity for a great one.

To save money, Rhythm's leadership considered canceling a clinical study because the prevailing scientific logic suggested their drug wouldn't work. The study's unexpected, resounding success became the company's pivotal turning point, highlighting the value of pursuing scientifically contrarian ideas.

Facing a preclinical safety signal, Arrowhead scrapped its entire Phase 2b pipeline to focus on a superior technology platform. This tough decision, which punished the stock short-term, built the foundation for their current successful pipeline and massive market cap.

Since the failure and market withdrawal of Relyvrio, regulators now require a higher standard of evidence for ALS drugs. A marginal signal is insufficient; companies must show a clear, coherent story across function, survival, and biomarkers to gain approval and convince payers.